Agreement drives continued patient access to four important therapies in Japan and Korea Strengthens Essential Pharma and Clinigen’s combined market presence in the JAPAC region Egham, UK – 6th February 2025 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche [...]
Provides significant resources to build on diversified portfolio of established and rare disease medicines Egham, UK – 12 December 2024 – Essential Pharma (“Essential” or “the Company”), an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, today announces the completion of [...]
Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type The acquisition ensures continued access to this essential cholinesterase inhibitor for dementia patients in key markets Significant addition to Essential Pharma’s portfolio of specialty central nervous system (CNS) medicines and further expands the company’s presence [...]
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma portfolio and second product within rare disease Egham, UK – 9 April 2024 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have [...]
ZUG, Switzerland and EGHAM, United Kingdom and RIYADH, Saudi Arabia, March 26, 2024 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has signed a Distribution Agreement with AcedrA BioPharmaceuticals (“AcedrA”), a [...]
Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients The acquisition will help ensure continued access to an important medicine for this vulnerable patient population First rare disease medicine to be added to the Essential Pharma product portfolio [...]
Zug, Switzerland & Egham, UK, Dec. 15 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the transfer of the UK marketing authorisations for IOPIDINE® (apraclonidine) in both available concentrations, IOPIDINE® 0.5% and [...]
Zug, Switzerland, Dec. 7 (Korea Bizwire) – Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of HALDOL® (haloperidol) and HALDOL® Decanoate (haloperidol decanoate) from Janssen Pharmaceutica NV. HALDOL® is a first-generation [...]